Relapsed or Refractory Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Relapsed or Refractory Renal Cell Carcinoma (RCC) Market Outlook
Thelansis’s “Relapsed or Refractory
Renal Cell Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Relapsed
or Refractory Renal Cell Carcinoma (RCC) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Relapsed
or Refractory Renal Cell Carcinoma (RCC) Overview
Renal cell
carcinoma (RCC) represents the predominant form of kidney cancer, constituting
approximately 90% of all renal malignancies. Several factors, including tumor
stage at diagnosis, patient age, overall health, and tumor mutation profiles,
influence the prognosis of RCC. Refractory or relapsed RCC is observed in 20%
to 30% of patients. Although the 5-year overall survival rate for RCC patients
is approximately 75%, the median survival for those with refractory or relapsed
disease is only 19 to 37 months, underscoring the necessity for efficacious
later-line treatments. The management of advanced RCC is particularly
challenging and necessitates a comprehensive understanding of the evolving
treatment landscape. Various therapeutic agents, including vascular endothelial
growth factor receptor (VEGFR) tyrosine kinase inhibitors, immune checkpoint
inhibitors, and mTOR inhibitors, have been approved for treating advanced RCC.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment